Alimera Sciences Inc

Alimera Sciences — Investor Day (July 2012)

54 slides from Alimera Sciences's investor day presentation, Jul 18, 2012

  1. Slide 1: Key Learning: A Significant Percentage of Patients Do Not Achieve 20/40 or Better Vision

    Key Learning: A Significant Percentage of Patients Do Not Achieve 20/40 or Better Vision In the EU, roughly half of DME patients are able to achieve a "drivable" BCVA or better over the long term, but a full third (32.6%) remain at 20/80 or worse. Success levels are similar for the EU & US. 1 EU - S

  2. Slide 2: 37% of Patients Do Not Achieve 20/40 Outcome From Lucentis US Clinical Trial Results

    37% of Patients Do Not Achieve 20/40 Outcome From Lucentis(r) US Clinical Trial Results (RIDE/RISE) 24 Injections in Protocol Naive Patients in Protocol 2 Ranibizumab for Diabetic Macular Edema, Nguyen et al., Ophthalmology Apr. 2012

  3. Slide 3: 47% of Patients Do Not Achieve 20/40 Outcome From Lucentis EU Clinical Trial Results

    47% of Patients Do Not Achieve 20/40 Outcome From Lucentis(r) EU Clinical Trial Results (RESTORE) 3 The RESTORE Study, Mitchell et al. Ophthalmology, 2011.

  4. Slide 4: Understanding Treatment Patterns for Insufficiently Responsive Patients

    Understanding Treatment Patterns for Insufficiently Responsive Patients Basic Idea: To determine parameters whereby vision should be considered as an indicator for changing treatment algorithms for a patient. 4 Visual Acuity 20/60 20/40 20/50 20/80 20/100 Injection # 1 2 3 4 5 6 7 8 9 10 11 12 Maint

  5. Slide 5: EU Advisory Boards Provide an Understanding of Insufficiently Responsive Patients: 4th Visit

    EU Advisory Boards Provide an Understanding of Insufficiently Responsive Patients By the 4th visit, 52% of Advisors would use ILUVIEN in patients with 20/50 vision and 93% would use in patients with 20/80 vision. Switch or Add ILUVIEN by the 4th Visit - Total 5 20/50 20/80 (n=155) (n=164) Note: EU r

  6. Slide 6: EU Advisory Boards Provide an Understanding of Insufficiently Responsive Patients: 7th Visit

    EU Advisory Boards Provide an Understanding of Insufficiently Responsive Patients By the 7th visit, conversion rates continued to climb. Switch or Add ILUVIEN by the 7th Visit - Total 6 20/50 20/80 (n=138) (n=97)

  7. Slide 7: Quantitative Research Overview

    Quantitative Research Overview 7 EU Sample Size of 175 Physicians July 2012 Statistically Significant Samples Per Country Consistent Stimulus #'s indicate physicians per country

  8. Slide 8: Insufficiently Responsive Exercise Results (Quantitative)

    Insufficiently Responsive Exercise Results (Quantitative) Insufficiently Responsive Patient Exercise - ILUVIEN Cumulative Frequency from Post-ILUVIEN Data Exposure 8 (n=175) ILUVIEN EU Baseline ATU Quantitative Marketing Research, Scimedica Group, July 2012.

  9. Slide 9: ILUVIEN Market Share; Existing Patients

    ILUVIEN Market Share; Existing Patients Total EU Current Treatment* for Existing DME Patients * Pharmacologics used alone or combined with laser (n=175) ILUVIEN EU Baseline ATU Quantitative Marketing Research, Scimedica Group, July 2012. Total EU Revised Treatment* for Existing DME Patients with ILU

  10. Slide 10: ILUVIEN Market Share: New Patients

    ILUVIEN Market Share: New Patients Estimated ILUVIEN Use In comparison, US total ILUVIEN New share estimated at 10.2%. 10 Total EU Current Treatment* for New DME Patients Total EU Revised Treatment* for New DME Patients with ILUVIEN Pharmacologics used alone or combined with laser (n=175) ILUVIEN EU

  11. Slide 11: Key Reasons for Using ILUVIEN

    Key Reasons for Using ILUVIEN 11 ILUVIEN EU Baseline ATU Quantitative Marketing Research, Scimedica Group, July 2012.(n=175)

  12. Slide 12: Key Reasons for Not Using ILUVIEN

    Key Reasons for Not Using ILUVIEN(r) ILUVIEN EU Baseline ATU Quantitative Marketing Research, Scimedica Group, July 2012.(n=175) 12

  13. Slide 13: European Expansion

    C European Expansion WM Approved In Process mm MRP Countries

  14. Slide 14: Physician Response Qualitative and Quantitative Findings

    Physician Response Qualitative and Quantitative Findings Dave Holland, Co-Founder, SVP, Sales and Marketing

  15. Slide 15: Engaging Retinal-Treating Physicians

    Engaging Retinal-Treating Physicians Meeting Interaction Advisory Boards Quantitative ATU Data 2

  16. Slide 16: Physician Engagements

    Physician Engagements EU Programs Completion Date Audience ILUVIEN Scientific Advisory Boards 2010-2011 25 ILUVIEN Steering Committee Meeting 1/14/12 11 Euretina Advisory Board 1/28/12 20 WOC Advisory Board 2/18/12 (2 Sessions) 40 German Advisory Board 3/9/12 17 French Advisory Board 4/26/12 13 ARVO

  17. Slide 17: Physician Response to ILUVIEN

    Physician Response to ILUVIEN 4 Desire for ILUVIEN is Strong Physicians acknowledge their greatest unmet need in treating DME is therapies that can provide a sustained duration of effect Physicians recognize that a sizeable portion of their population is chronic and needs therapy beyond laser and an

  18. Slide 18: Key Learning: Current Visual Acuity Key to Risk Tolerance

    Key Learning: Current Visual Acuity Key to Risk Tolerance Takeaways: The concern over risk of IOP elevation diminishes as vision worsens Potential for blindness or poor vision takes precedence over IOP management 5 Time with DME Visual Acuity Good Vision 20/20 to 20/40 Poor Vision (<20/60) Relevance

  19. Slide 19: Key Learning: DME Treatment Paradigm in EU Includes 2nd Line Use of Steroids

    Key Learning: DME Treatment Paradigm in EU Includes 2nd Line Use of Steroids EU treatment paradigm for DME with vision loss 6 Pricespective EU HTA Advisory Board Sept 2011 1st line 2nd line Some laser combo Some laser combo ~50% laser combo + Majority laser

  20. Slide 20: Key Learning: Awareness that DME is Not a Static Disease

    Key Learning: Awareness that DME is Not a Static Disease Prolonged Inflammation Associated with DME May Cause Cumulative Damage Changes to the Retinal Structure May Be Occurring and Duration of Disease Appears to be Linked New Factors Become Important for Consideration in Treating DME These may not

  21. Slide 21: Key Learning: OCT Status is Not Necessarily An Indicator of Peak VA Gain

    Key Learning: OCT Status is Not Necessarily An Indicator of Peak VA Gain Opportunity Both steroids and anti-VEGF's reduce retinal thickening and improve vision. In chronic DME patients, ILUVIEN delivers improved visual outcomes, despite similar reduction in retinal thickness. 8 Similar anatomy but v

  22. Slide 22: Key Learning: Existing Versus New Patient Populations

    Key Learning: Existing Versus New Patient Populations 9 9 Average across the 7 countries Source: ILUVIEN EU Baseline ATU Quantitative Marketing Research, Scimedica Group, July 2012.

  23. Slide 23: Key Learning: A Significant Percentage of Patients Do Not Achieve 20/40 or Better Vision

    Key Learning: A Significant Percentage of Patients Do Not Achieve 20/40 or Better Vision In the EU, roughly half of DME patients are able to achieve a "drivable" BCVA or better over the long term, but a full third (32.6%) remain at 20/80 or worse. Success levels are similar for the EU & US. 10 EU -

  24. Slide 24: Example of 20/20 Vision

    Example of 20/20 Vision Example of 20/20 Vision

  25. Slide 25: Example of 20/40 Vision

    Example of 20/40 Vision Example of 20/40 Vision

  26. Slide 26: Example of 20/70 Vision

    Example of 20/70 Vision 13 13

  27. Slide 27: Example of 20/200 Vision

    Example of 20/200 Vision Example of 20/200 Vision

  28. Slide 28: Key Learning: A Significant Percentage of Patients Do Not Achieve 20/40 or Better Vision

    Key Learning: A Significant Percentage of Patients Do Not Achieve 20/40 or Better Vision In the EU, roughly half of DME patients are able to achieve a "drivable" BCVA or better over the long term, but a full third (32.6%) remain at 20/80 or worse. Success levels are similar for the EU & US. 1 EU - S

  29. Slide 29: 37% of Patients Do Not Achieve 20/40 Outcome From Lucentis US Clinical Trial Results

    37% of Patients Do Not Achieve 20/40 Outcome From Lucentis(r) US Clinical Trial Results (RIDE/RISE) 24 Injections in Protocol Naive Patients in Protocol 2 Ranibizumab for Diabetic Macular Edema, Nguyen et al., Ophthalmology Apr. 2012

  30. Slide 30: 47% of Patients Do Not Achieve 20/40 Outcome From Lucentis EU Clinical Trial Results

    47% of Patients Do Not Achieve 20/40 Outcome From Lucentis(r) EU Clinical Trial Results (RESTORE) 3 The RESTORE Study, Mitchell et al. Ophthalmology, 2011.

  31. Slide 31: Understanding Treatment Patterns for Insufficiently Responsive Patients

    Understanding Treatment Patterns for Insufficiently Responsive Patients Basic Idea: To determine parameters whereby vision should be considered as an indicator for changing treatment algorithms for a patient. 4 Visual Acuity 20/60 20/40 20/50 20/80 20/100 Injection # 1 2 3 4 5 6 7 8 9 10 11 12 Maint

  32. Slide 32: EU Advisory Boards Provide an Understanding of Insufficiently Responsive Patients: 4th Visit

    EU Advisory Boards Provide an Understanding of Insufficiently Responsive Patients By the 4th visit, 52% of Advisors would use ILUVIEN in patients with 20/50 vision and 93% would use in patients with 20/80 vision. Switch or Add ILUVIEN by the 4th Visit - Total 5 20/50 20/80 (n=155) (n=164) Note: EU r

  33. Slide 33: EU Advisory Boards Provide an Understanding of Insufficiently Responsive Patients: 7th Visit

    EU Advisory Boards Provide an Understanding of Insufficiently Responsive Patients By the 7th visit, conversion rates continued to climb. Switch or Add ILUVIEN by the 7th Visit - Total 6 20/50 20/80 (n=138) (n=97)

  34. Slide 34: Quantitative Research Overview

    Quantitative Research Overview 7 EU Sample Size of 175 Physicians July 2012 Statistically Significant Samples Per Country Consistent Stimulus #'s indicate physicians per country

  35. Slide 35: Insufficiently Responsive Exercise Results (Quantitative)

    Insufficiently Responsive Exercise Results (Quantitative) Insufficiently Responsive Patient Exercise - ILUVIEN Cumulative Frequency from Post-ILUVIEN Data Exposure 8 (n=175) ILUVIEN EU Baseline ATU Quantitative Marketing Research, Scimedica Group, July 2012.

  36. Slide 36: ILUVIEN Market Share; Existing Patients

    ILUVIEN Market Share; Existing Patients Total EU Current Treatment* for Existing DME Patients * Pharmacologics used alone or combined with laser (n=175) ILUVIEN EU Baseline ATU Quantitative Marketing Research, Scimedica Group, July 2012. Total EU Revised Treatment* for Existing DME Patients with ILU

  37. Slide 37: ILUVIEN Market Share: New Patients

    ILUVIEN Market Share: New Patients Estimated ILUVIEN Use In comparison, US total ILUVIEN New share estimated at 10.2%. 10 Total EU Current Treatment* for New DME Patients Total EU Revised Treatment* for New DME Patients with ILUVIEN Pharmacologics used alone or combined with laser (n=175) ILUVIEN EU

  38. Slide 38: Key Reasons for Using ILUVIEN

    Key Reasons for Using ILUVIEN 11 ILUVIEN EU Baseline ATU Quantitative Marketing Research, Scimedica Group, July 2012.(n=175)

  39. Slide 39: Key Reasons for Not Using ILUVIEN

    Key Reasons for Not Using ILUVIEN(r) ILUVIEN EU Baseline ATU Quantitative Marketing Research, Scimedica Group, July 2012.(n=175) 12

  40. Slide 40: Pricing and Reimbursement

    Pricing and Reimbursement

  41. Slide 41: Market Access Progress for ILUVIEN

    Market Access Progress for ILUVIEN Completed Work Cost Effectiveness and Budget Impact Models Global Value Dossier Engagement with Consultants Work in Progress Preparation of Country Dossiers (France, Spain and Italy) NICE Committee Meeting Progress Submissions to AWMSG and SMC Germany Update Austri

  42. Slide 42: Planned National Price for ILUVIEN

    Planned National Price for ILUVIEN The ceiling price is recommended target price in each market (MSP) Price will be negotiated down from this target in national/regional negotiations Expect €3500 - €5500 net pricing 2 ILUVIEN EU price corridor (MSP per unit) Ozurdex tri-annual (6 inj)

  43. Slide 43: Market Opportunity and Launch Timing

    Market Opportunity and Launch Timing Rick Eiswirth, COO & CFO

  44. Slide 44: European Launch Strategy

    European Launch Strategy Pursue Direct Commercial Launch in Northern European Markets Evaluate Options and Timing in the Economically Challenged Southern European Markets Pursue Expansion Through the Mutual Recognition Procedure 4

  45. Slide 45: Persons with Diabetes and CSME by Country

    Country Persons with Diabetes1 Persons Diagnosed with Diabetes2 Person Diagnosed with Diabetes with CSME3 Existing CSME Patients4 Germany 5,022,000 3,163,860 215,499 142,203 UK ** 3,064,000 1,930,320 131,455 89,389 France 3,238,000 2,039,940 138,920 95,855 Italy 3,560,000 2,242,800 152,735 97,750 Sp

  46. Slide 46: Estimated ILUVIEN Launch Dates

    Estimated ILUVIEN(r) Launch Dates 6 2013 2014 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan DE UK FR IT ES PT AT Benelux and Nordic Regions Benelux and Nordic Regions Benelux and Nordic Regions

  47. Slide 47: EU Revenue Expectation

    EU 4 Revenue Expectation: 2013 2014 2015 2016 2017 =Germany Austria sUK — France ALIME! SCIENCE

  48. Slide 48: Existing Patients Opportunity

    Existing Patients Oppor ry < = = 2013 2014 2015 2016 2017 EU 4 Existing Patients ALIMER SCHENCIY

  49. Slide 49: Existing Patients Opportunity

    Existing Patients Opportunity 9 9

  50. Slide 50: EU Expansion Opportunity

    EU Expansion Opportunity EU Expansion Opportunity

  51. Slide 51: $40 Million Equity Raise

    $40 Million Equity Raise Have agreed to sell $40 million Series A Convertible Preferred Stock to new and existing investors (Palo Alto Investors, LLC, Sofinnova Venture Partners and New Enterprise Advisors) The initial conversion price will be $2.91 ~ 13.75 million common share equivalents 30% warra

  52. Slide 52: Commercial Next Steps

    Commercial Next Steps Dan Myers, Co-Founder, President and CEO

  53. Slide 53: Commercial Activity

    Commercial Activity Streamlined EU Commercial Structure Similar to US Launch Plans Alimera Management Group Based in EU Leveraging Third Party Expertise 3PL Outsourcing 100% Dedicated Contract Sales Force Ongoing Activity Communications Development Leveraging US Work Congress and Advisory Board Plan

  54. Slide 54: Retinal Disease Is Our Focus: 2012 Analyst Day Q&A

    RETINAL DISEASE IS OUR FOCUS 2012 Analyst Day Q&A Session ~ .

Alimera Sciences — Investor Day (July 2012) on 6ix